ATORVASTATIN SANDOZ atorvastatin 40 mg film-coated tablet blister pack

Country: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

atorvastatin calcium trihydrate, Quantity: 43.3 mg

Disponibbli minn:

Sandoz Pty Ltd

Għamla farmaċewtika:

Tablet, film coated

Kompożizzjoni:

Excipient Ingredients: magnesium stearate; macrogol 6000; hyprolose; titanium dioxide; lactose monohydrate; microcrystalline cellulose; polysorbate 80; croscarmellose sodium; calcium carbonate; hypromellose

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

30

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

Atorvastatin Sandoz is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. Prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemia, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated.,Atorvastatin Sandoz is indicated in hypertensive patients with multiple risk factors for coronary heart disease (CHD) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic CHD to reduce the risk of non-fatal myocardial infarction (MI) and non-fatal stroke.,These effects do not replace the need to independently control known causes of cardiovascular (CV) mortality and morbidity such as hypertension, diabetes and smoking

Sommarju tal-prodott:

Visual Identification: White to off-white, round, biconvex film coated tablet debossed with A40 on one side, and cross scored breaking notch on the other side; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 20 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Child resistant closure

L-istatus ta 'awtorizzazzjoni:

Registered

Data ta 'l-awtorizzazzjoni:

2020-12-10